Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease

Analytical and Bioanalytical Chemistry

Volumn 406, Issue 28, 2014, Pages 7137-7148

  Gonzalez Dominguez R ^a   Garcia Barrera T ^a   Gomez Ariza J L ^a  

^a UNIVERSITY OF HUELVA   (Spain)

Author keywords

Alzheimer's disease; Biomarkers; Direct infusion mass spectrometry; Metabolomics

Indexed keywords

BIOMARKERS; BODY FLUIDS; MASS SPECTROMETRY; METABOLISM; MULTIVARIANT ANALYSIS; NEURODEGENERATIVE DISEASES; PHOSPHOLIPIDS; SATURATED FATTY ACIDS; STATISTICAL MECHANICS;

ALZHEIMER'S DISEASE; ANALYTICAL APPROACH; DIRECT INFUSION MASS SPECTROMETRIES; ELECTROSPRAY MASS SPECTROMETRY; MASS SPECTROMETRY ANALYSIS; MEMBRANE DESTABILIZATION; METABOLIC FINGERPRINTING; METABOLOMICS;

DIAGNOSIS;

BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; METABOLOME; METABOLOMICS; PROCEDURES;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS;

EID: 84919742683     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-8102-3     Document Type: Article

References (79)

1. Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, Litchfield S, Smith A, Barnetson L, Smith AD (1995) Relative role of plaques and tangles in the dementia of Alzheimer disease: correlations using three sets of neuropathological criteria. Dementia 6:21-31
2. Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L (2005) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 26:587-595
3. Maruszak A, Żekanowski C (2011) Mitochondrial dysfunction and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 35:320-330
4. González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2014) Characterization of metal profiles in serum during the progression of Alzheimer's disease. Metallomics 6:292-300
5. Mielke MM, Lyketsos CG (2006) Lipids and the pathogenesis of Alzheimer's disease: is there a link? Int Rev Psychiatry 18:173-186
6. Lindon JC, Holmes E, Nicholson JK (2004) Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diagn 4:189-199
7. McKahnn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939-944
8. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734-746
9. Craig-Schapiro R, Fagan AM, Holtzman DM (2009) Biomarkers of Alzheimer's disease. Neurobiol Dis 35:128-140
10. Kuehnbaum NL, Britz-McKibbin P (2013) New advances in separation science formetabolomics: resolving chemical diversity in a postgenomic era. Chem Rev 113:2437-2468
11. Kuehnbaum NL, Kormendi A, Britz-McKibbin P (2013) Multisegment injection-capillary electrophoresis-mass spectrometry: a high-throughput platform for metabolomics with high data fidelity. Anal Chem 85:10664-10669
12. Huang MZ, Cheng SC, Cho YT, Shiea J (2011) Ambient ionization mass spectrometry: a tutorial. Anal Chim Acta 702:1-15
13. Draper J, Lloyd AJ, Goodacre R, Beckmann M (2013) Flow infusion electrospray ionisation mass spectrometry for high throughput, non-targeted metabolite fingerprinting: a review. Metabolomics 9:S4-S29
14. Oresic M, Hyötyläinen T, Herukka SK, Sysi-Aho M, Mattila I, Seppänan-Laakso T, Julkunen V, Gopalacharyulu PV, Hallikainen M, Koikkalainen J, Kivipelto M, Helisalmi S, Lötjönen J, Soininen H (2011) Metabolome in progression to Alzheimer's disease. Transl Psychiatry 1:e57
15. Czech C, Berndt P, Busch K, Schmitz O, Wiemer J, Most V, Hampel H, Kastler J, Senn H (2012) Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS ONE 7:e31501
16. Trushina E, Dutta T, Persson XMT, Mielke MM, Petersen RC (2013) Identification of altered betabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS ONE 8:e63644
17. Ibánez C, Simó C, Barupal DK, Fiehn O, Kivipelto M, Cedazo-Mínguez A, Cifuentes A (2013) A new metabolomic workflow for early detection of Alzheimer's disease. J Chromatogr A 1302:65-71
18. Ibáñez C, Simó C, Martín-Álvarez PJ, Kivipelto M, Winblad B, Cedazo-Mínguez A, Cifuentes A (2012) Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem 84:8532-8540
19. Lin S, Liu H, Kanawati B, Liu L, Dong J, Li M, Huang J, Schmitt-Kopplin P, Cai Z (2013) Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer's disease in CRND8 mice. Anal Bioanal Chem 405:5105-5117
20. Lin S, Kanawati B, Liu L, Witting M, Li M, Huang J, Schmitt-Kopplin P, Cai Z (2014) Ultra high resolution mass spectrometry-based metabolic characterization reveals cerebellum as a disturbed region in two animal models. Talanta 118:45-53
21. Sangster T, Major H, Plumb R, Wilson AJ, Wilson ID (2006) A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst 131:1075-1078
22. van den Berg RA, Hoefsloot HCJ, Westerhuis JA, Smilde AK, van der Werf MJ (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 7:142
23. Xia J, Broadhurst DI, Wilson M, Wishart DS (2013) Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 9:280-299
24. Pulfer M, Murphy RC (2003) Electrospray mass spectrometry of phospholipids. Mass Spectrom Rev 22:332-364
25. Wang C, Xie S, Yang J, Yang Q, Xu G (2004) Structural identification of human blood phospholipids using liquid chromatography/quadrupole-linear ion trap mass spectrometry. Anal Chim Acta 525: 1-10
26. Beckmann M, Parker D, Enot DP, Duval E, Draper J (2008) High-throughput, nontargeted metabolite fingerprinting using nominal mass flow injection electrospray mass spectrometry. Nat Protoc 3: 486-504
27. Graham SF, Chevallier OP, Roberts D, Hölscher C, Elliott CT, Green BD (2013) Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. Anal Chem 85:1803-1811
28. 1H NMR analysis of the polar metabolome of post-mortem brain tissue. Metabolomics in press
29. Dettmer K, Aronov PA, Hammock BD (2007) Mass spectrometry-based metabolomics. Mass Spectrom Rev 26:51-78
30. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C (2009) A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 30:1235-1239
31. Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, Shankle WR, Tomita M (2013) Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis 34:2865-2872
32. Wang G, Zhou Y, Huang FJ, Tang HD, Xu XH, Liu JJ, Wang Y, Deng YL, Ren RJ, Xu W, Ma JF, Zhang YN, Zhao AH, Chen SD, Jia W (2014) Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. J Proteome Res 13:2649-2658
33. Katajamaa M, Oresic M (2007) Data processing formass spectrometry-based metabolomics. J Chromatogr A 1158:318-328
34. Weaver PJ, Laures AMF, Wolff JC (2007) Investigation of the advanced functionalities of a hybrid quadrupole orthogonal acceleration time-of-flight mass spectrometer. Rapid Commun Mass Spectrom 21:2415-2421
35. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 89:1671-1675
36. Klein J (2000) Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 107:1027-1063
37. Kanfer JN, Pettegrew JW, Moossy J, McCartney DG (1993) Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's disease controls. Neurochem Res 18:331-334
38. Walter A, Korth U, Hilgert M, Hartmann J, Weichel O, Hilgert M, Fassbender K, Schmitt A, Klein J (2004) Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 25:1299-1303
39. Kosicek M, Kirsch S, Bene R, Trkanjec Z, Titlic M, Bindila L, Peter-Katalinic J, Hecimovic S (2010) Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer's disease patients - a pilot study. Anal Bioanal Chem 398:2929-2937
40. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ (2001) Brain membrane phospholipid alterations in alzheimer's disease. Neurochem Res 26:771-782
41. Conquer JA, Tierneyc MC, Zecevica J, Bettgera WJ, Fisher RH (2000) Fatty acid analysis of blood plasma of patients with alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35:1305-1312
42. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20:415-418
43. Kyle DJ, Schaefer E, Patton G, Beiser A (1999) Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 34:S245
44. Mulder C, Wahlund LO, Teerlink T, Blomberg M, Veerhuis R, van Kamp GJ, Scheltens P, Scheffer PG (2003) Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm 110:949-955
45. Ross M, Moszczynska A, Erlich J, Kish SJ (1998) Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem 70:786-793
46. Devore EE, Grodstein F, van Rooij FJA, Hofman A, Rosner B, Stampfer MJ, Witteman JC, Breteler MM (2009) Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 90:170-176
47. Gardiner M, Nilsson B, Rehncrona S, Siesjö BK (1981) Free fatty acids in the rat brain in moderate and severe hypoxia. J Neurochem 36:1500-1505
48. Wilson DM, Bindert LI (1997) Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol 150:2181-2195
49. Fraser T, Tayler H, Love S (2010) Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Res 35:503-513
50. Wang DC, Sun CH, Liu LY, Sun XH, Jin XW, Song WL, Liu XQ, Wan XL (2012) Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. Neurobiol Aging 33:1057-1066
51. Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, Morris MC (2012) Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 29:691-697
52. Farooqui AA, Rapoport SI, Horrocks LA (1997) Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. Neurochem Res 22:523-527
53. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PWK, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL (2007) Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48:2485-2498
54. Igarashi M, Ma M, Gao F, Kim HW, Rapoport SI, Rao JS (2011) Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis 24:507-517
55. Martinez M, Mougan I (1998) Fatty acid composition of human brain phospholipids during normal development. J Neurochem 71:2528-2533
56. Sato Y, Nakamura T, Aoshima K, Oda Y (2010) Quantitative and wide-ranging profiling of phospholipids in human plasma by two-dimensional liquid chromatography/mass spectrometry. Anal Chem 82:9858-9864
57. Li N, Liu W, Li W, Li S, Chen X, Bi K, He P (2010) Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin Biochem 43:992-997
58. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Aayley ACD (1992) Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 21:91-94
59. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU (2006) Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21:344-348
60. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 293:1566-1570
61. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18:457-461
62. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L (1999) Increased CSF F2-isoprostane concentration in probable AD. Neurology 52:562-565
63. Mecocci P, Polidori C, Cherubini A, Chionne F, Cecchetti R, Senin U (1998) Oxidative damage to DNA lympocytes from AD patients. Neurology 51:1014-1017
64. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG (2007) Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids 32:213-224
65. Makar TK, Cooper AJL, Tofel-Grehl B, Thaler HT, Blass JP (1995) Carnitine, carnitine acetyltransferase, and glutathione in Alzheimer brain. Neurochem Res 20:705-711
66. Bazan NG, Colangelo V, Lukiw WJ (2002) Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 68-69:197-210
67. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 36:811-822
68. Adhihetty PJ, Beal MF (2008) Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromol Med 10:275-290
69. Rubio JC, de Bustos F, Molina JA, Jimenez-Jimenez FJ, Benito-Leon J, Martin MA, Campos Y, Ortí-Pareja M, Cabrera-Valdivia F, Arenas J (1998) Cerebrospinal fluid carnitine levels in patients with Alzheimer's disease. J Neurol Sci 155:192-195
70. Kása P, Rakonczay Z, Gulya K (1997) The cholinergic system in Alzheimer's disease. Prog Neurobiol 52:511-535
71. Lin AP, Shic F, Enriquez C, Ross BD (2003) Reduced glutamate neurotransmission in patients with Alzheimer's disease - an in vivo 13C magnetic resonance spectroscopy study. MAGMA 16:29-42
72. Rissman RA, De Blas AL, Armstrong DM (2007) GABA(A) receptors in aging and Alzheimer's disease. J Neurochem 103:1285-1292
73. Chen C, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, Jobst KA, Francis PT (1996) Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. Neurochemistry 66:1592-1598
74. Storga D, Vrecko K, Birkmayer JGD, Reibnegger G (1996) Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett 203:29-32
75. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, Randle S, McGowan E, Emson PC, Griffin JL (2010) A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int 56:937-943
76. Grammas P (2011) Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation 8:26
77. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GHK, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant Ainnodatabeta in plasma. Neurobiol Dis 24:114-127
78. Fisher G, Lorenzo N, Abe H, Fujita E, Frey WH, Emory C, Di Fiore MM, D' Aniello A (1998) Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. Amino Acids 15:263-269
79. Ravaglia G, Forti P, Maioli F, Bianchi G, Martelli M, Talerico T, Servadei L, Zoli M, Mariani E (2004) Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. Am J Clin Nutr 80:483-488